Since direct hemoperfusion with polymyxin B immobilized fiber (PMX-DHP) received its product certification for use in Europe in 1998, several prospective randomized controlled trials (RCTs) have been conducted in European countries. The first RCT, performed in six European academic medical centers in 2005, concluded that PMX-DHP is associated with improved hemodynamic status and cardiac function. Subsequently, a meta-analysis of PMX-DHP was presented in Italy in 2007. This systematic review found positive effects of PMX-DHP on mean arterial pressure and dopamine/ dobutamine use, PaO2/FiO2 ratio, endotoxin removal, and mortality. However, like most trials on extracorporeal therapies, none of the studies was double-blinded. The EUPHAS study, a multicenter RCT performed in ten Italian intensive care units in 2009, found that PMX-DHP improved 28-day survival, blood pressure, vasopressor requirement, and degree of organ failure. However, investigators in Belgium and Canada pointed out that there was no statistical difference in 28-day survival. Two more RCTs, the ABDO-MIX and EUPHRATES studies, the primary end points of which are 28-day mortality, were started in Europe and the United States at the end of 2010. We are hoping that these RCTs will resolve this issue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-010-4504-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of Trends and Influencing Factors of Cytokine-Adsorbing Therapies: A Nationwide Ecological Study in Japan.
Cureus
November 2024
Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, JPN.
Background: Cytokine-adsorption therapy has garnered attention as a potential treatment for conditions such as sepsis, although supporting evidence remains limited. Consequently, its utilization is expected to vary significantly across regions. To date, no ecological studies have investigated this regional heterogeneity.
View Article and Find Full Text PDFDirect hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study.
Respir Investig
December 2024
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama, Kanagawa, 236-0051, Japan.
Article Synopsis
- - A study investigated the effects of polymyxin B-immobilized fiber column (PMX) treatment on patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), who typically have a poor prognosis.
- - Results showed a survival rate of 65% at day 28 after PMX treatment, which is significantly higher than the usual 40% survival rate seen with conventional treatments.
- - The study concluded that PMX treatment is safe and potentially improves oxygenation and overall prognosis for AE-IPF patients.
Article Synopsis
- The study examined 33 severe COVID-19 patients who underwent a novel hemoperfusion therapy using the Seraph100 filter, aiming to reduce viral RNA levels and markers of inflammation.
- Results showed that while the initial levels of SARS-CoV-2 RNA were generally low and did not significantly change post-treatment, five inflammatory protein analytes exhibited notable decreases, indicating some therapeutic effect on inflammation and endothelial damage.
- The conclusion highlighted that Seraph 100 did not effectively lower viral RNA levels, but it did successfully reduce several inflammatory markers in the blood of these patients.
Risk Factors for Postoperative Mortality in Patients with Colorectal Diverticular Perforation.
J Anus Rectum Colon
October 2024
Department of Surgery, Fukuoka Tokushukai Hospital, Kasuga, Japan.
Objectives: The prognosis of patients with colorectal diverticular perforations requiring surgery is poor, and the efficacy of polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) in these patients has not yet been established. In the present study, we evaluated the prognostic factors and the efficacy of PMX-DHP in surgically treated patients with perforated colorectal diverticula.
Methods: Of the 116 patients with colorectal perforations who underwent emergency surgery at our hospital between April 2018 and May 2023, we retrospectively reviewed 46 patients with perforated colorectal diverticula.
The polymyxin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine PMX-OPTIC study: A multicenter retrospective observational study.
Artif Organs
September 2024
Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Background: Polymyxin-B direct hemoperfusion (PMX-DHP) is an endotoxin adsorption column-based blood purification therapy. Since one of the most potent effects of PMX-DHP is blood pressure elevations, it may be the most effective when it is introduced at the time when the need for vasopressors is the greatest, which, in turn, may reduce mortality.
Methods: A multicenter retrospective study was conducted at 24 ICUs in Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!